Pemigatinib 是一种口服具有活力的，选择性的FGFR抑制剂，能够作用于 FGFR1 (IC50:0.4 nM)，FGFR2 (IC50:0.5 nM)，FGFR3 (IC50:1.2 nM)，FGFR4 (IC50:30 nM)，有用于胆管癌的潜力。

Pemigatinib is an orally active, selective inhibitor of FGFR(IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively).

In cells expressing FGFR2-CLIP1 fusion are sensitive to Pemigatinib (INCB054828; IC50 value of 10.16 nM)[3].

1513857-77-6

C24H27F2N5O4

487.5

INCB054828

DMSO:40mg/mL (82.05 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years